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Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-
treated renal transplants. The influence of antihypertensive treatment
on the long-term evolution of arterial pressure and renal function was
studied in a prospective controlled trial conducted in renal transplant
recipients treated by cyclosporine. Within six months after transplan-
tation, patients were randomly allocated to treatment by the angioten-
sin-converting enzyme inhibitor, lisinopril (ACEI, alone or associated
with frusemide; N = 14), or the calcium antagonist, nifedipine (CA,
alone or associated with atenolol; N = 11). Glomerular filtration rate
(TCDTPA clearance) and effective renal plasma flow (hippuran clear-
ance) as well as 24-hour urinary excretion of electrolytes and albumin
were estimated at about I and 2.5 years of follow-up. Before initiation
of antihypertensive therapy, the two groups were similar with regards
to mean arterial pressure (119 2 vs. 120 4 mm Hg), effective renal
plasma flow (285 26 vs. 248 33 ml/minll .73 m2) and glomerular
filtration rate (59 4 vs. 61 8 ml/min/1.73 m2 in the ACE! and CA
groups, respectively). Both ACEI and CA treatments were associated
with no change in renal function, a similar change in mean arterial
pressure (ACE! —18 3; CA —13 5 mm Hg) and identical trough
blood levels of cyclosporine. Urinary albumin excretion did not change
significantly in any groups. Of interest, only in the ACEI group did
filtration fraction significantly decrease (from 0.22 0.01% to 0.19
0.01% at final studies). These results indicate that in cyclosporine-
treated transplant recipients, a satisfactory control of hypertension is
obtained by chronic ACEI, which is as effective on arterial pressure as
a combination of CA and atenolol. A consistent reduction of arterial
pressure by either treatment seems to afford a similar degree of renal
protection in long-term cyclosporine treated patients.
In addition to being an important risk factor for cardiovascu-
lar disease, arterial hypertension may accelerate the deteriora-
tion of renal function in primary parenchymal renal disease [1]
as well as in the transplanted kidney [2, 31. In fact, this model
is characterized by the association of hypertension with several
factors known to affect nephron loss such as chronic rejection,
recurrence of native kidney disease and cyclosporine nephro-
toxicity superimposed on a single kidney.
The use of cyclosporine is associated with a high prevalence
of hypertension [4]. In contrast with the frequent renin depen-
dency of hypertension in patients maintained on conventional
immunosuppressive therapy [5, 61, hypertension observed in
cyclosporine-treated patients is characterized by sodium depen-
dency [7], enhanced sympathetic nervous system activity [81,
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marked intrarenal vasoconstriction predominant at the afferent
level [9] and rather low renin values when compared to patients
maintained on conventional immunosuppression [10, 11], re-
sulting from expansion of extracellular fluid volume [121 and
possibly an impairment in the processing of prorenin into active
renin [9]. All these postulated mechanisms of cyclosporine-
associated hypertension are in favor of the use of calcium
channel blockers rather than angiotensin-converting enzyme
inhibitors (ACEI). Acute blockade of angiotensin generation is
poorly active on arterial pressure and renal hemodynamics in
such patients [11] and the pretreatment by ACEI has no
influence on the renal effect of cyclosporine in animal studies
[13, 14]. In contrast, it was shown that calcium antagonists may
prevent the deleterious functional renal effect of CsA in some
animal experiments [15—17].
The present randomized study was undertaken to assess the
long-term effect of the angiotensin-converting enzyme inhibitor,
lisinopril, and the calcium antagonist, nifedipine, on arterial
pressure and renal function in renal transplant recipients who
were maintained on cyclosporine.
Methods
Patients
Thirty-one hypertensive cadaver (N = 27) or living-related
haploidentical (N = 4) kidney recipients were enrolled in the
present studies. Primary renal disease was glomerulonephritis
in 16, polycystic kidney disease in two, interstitial nephritis and
uropathy in eight, nephroangiosclerosis in three and other in
two. Hypertension was defined by diastolic blood pressure
readings above 95 mm Hg on at least three outpatient visits. No
antihypertensive medications were given between time of trans-
plantation and inclusion in the present studies. All patients had
stable renal function (serum creatinine lower than 200 mol/
liter for at least 3 months), no signs of rejection and received
cyctosporine. Following initial determination of renal function
and hemodynamics, patients were randomly assigned to treat-
ment by the angiotensin-converting enzyme inhibitor, lisinopril
(ACE!, N 16) or the calcium antagonist, nifedipine (CA, N =
15), given as a slow release preparation. The initial dose of
lisinopril was 5 mg qd; this dose was increased to 10 and 15 mg
qd and frusemide (40 to 80 mg/day) was added if hypertension
was not satisfactorily controlled (diastolic blood pressure
higher than 95 mm Hg at 2 successive outpatient visits). The
initial dose of nifedipine was 20 mg qd; this dose was increased
to 20 mg bid and 20 mg tid when necessary. In some patients,
419
420 Mourad et a!: CsA and antihypertensive therapy
the beta blocker atenolol was added at a dose of 50 mg qd to
attenuate undesirable side effects of nifedipine or to reinforce
the antihypertensive effect of the calcium antagonist. Patients
were seen monthly at the outpatient clinic, and renal function
was again assessed after approximately 1 (intermediate study)
and 2.5 years (final study) of antihypertensive treatment. Pa-
tients were maintained on their usual sodium and protein
intakes but advised not to ingest excessive amounts of both.
Cyclosporine was given in a split dose twice daily and dosage
was adjusted according to the whole blood trough cyclosporine
level, the aim being a concentration of about 150 ng/ml at six
months post-transplantation and 100 ng/ml thereafter. Whole
blood trough level of cyclosporine was determined using a
monoclonal monospecific antibody (Sandimmun kit, Sandoz,
Basel, Switzerland). Prednisolone dose was tapered in a step-
wise fashion and maintained at 10 mg qd one year post-
transplantation. All patients received azathioprine I mg/kg/day
during the first six months of post-transplantation. The protocol
was approved by the ethical committee of our institution and all
patients gave their informed consent.
Determination of renal function
Patients were asked to come to the outpatient clinic with a
24-hour urinary collection for determination of sodium, potas-
sium, urea, creatinine and albumin. Studies were performed
between 8 and 12 a.m. Heart rate and arterial pressure were
monitored every three minutes using an automatic device
(Dynamap 845 XT, Critikon, France). Glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF) were estimated
by clearances of technetium-labeled diethylenetriaminopen-
taacetic acid (99mTcDTPA) and '311-ortho iodohippurate, using
the constant infusion technique as previously described [181.
Briefly, after induction of water diuresis (10 ml/kg) and a
90-minute equilibration period, four 20-minute urine collections
were obtained by spontaneous voiding. At the end of each
clearance period, blood was drawn for determination of plasma
radioactivity and hematocrit. Before clearance determination,
blood was also obtained for the measurement of cyclosporine
trough level, plasma concentrations of creatinine and electro-
lytes, plasma renin activity (PRA) and plasma aldosterone
concentration (PAC). In each urine sample, concentrations of
creatinine, electrolytes and albumin were determined.
Laboratory methods
PRA and PAC were estimated by radioimmunoassay tech-
niques (CEA, Sorin kits). Urinary albumin was measured by
radioimmunoassay (Pharmacia albumin RIA, Pharmacia Diag-
nostics AB, Uppsala, Sweden). Chemical analyses of plasma
and urine were performed using standard clinical laboratory
techniques.
Calculations and statistical analysis
All clearances were calculated as the average of the four
collection periods and conected for body surface area. Renal
blood flow (RBF) was calculated as ERPF/(l — hematocrit),
and renal vascular resistances as mean arterial pressure (MAP)!
RBF and expressed in mm Hg ml1 mm.
Values were expressed as mean and standard error of the
mean (sEM). The effect of treatment on any parameter was
assessed by the t-test for paired data and comparison between
Table 1. Baseline parameters (mean SEM)
ACEI
group CA group
Number of patients 14 11
SexF/M 3/11 4/7
Age of recipients years 40 3 50 4
Age of donors years 31 3 33 3
Time after transplantation months 5 1 5 I
Number of acute rejections prior to inclusion 8/14 6/11
Body weightkg 63±4 68 3
Systolic arterial pressure mm Hg 161 4 167 6
Diastolic arterial pressure mm Hg 98 2 97 4
Mean arterial pressure mm Hg 119 2 120 4
Heartrate(bpm) 64 2 64±4
Serum creatinine smol/1iter 140 6 137 9
Glomerular filtration rate ml/min/1.73 in2 59 4 61 8
Effective renal plasma flow ml/min/1.73 m2 285 26 248 33
Renal vascular resistance mm Hg/mi/mm 0.29 0.02 0.34 0.04
Filtration fraction % 21.7 1.2 25.5 1.8
Urinary albumin excretion jtg/min 82 33 111 44
a P < 0.05 between groups.
groups by analysis of variance. A P value of less than 0.05 was
considered significant.
Results
Of the 16 patients assigned to ACEI treatment, 14 completed
the study; one patient was excluded due to pregnancy and one
for severe acute graft rejection. Renal function was assessed in
this group after 12 1 (intermediate study) and 30 2 months
(final study) of therapy. Among the 15 patients included in the
CA group, only 11 were again studied 10 1 (intermediate
study) and 30 2 months (final study) after initiation of
therapy. Four patients were excluded for the following reasons:
discovery of an aldosterone-secreting adrenal tumor following
observation of consistent hypokalemia in one patient, renal
transplant artery stenosis in one patient and biopsy-proven
chronic rejection in the remaining two. Thus, statistical analysis
was carried out in 14 patients of the ACEI-treated group and 11
of the CA-treated group. The mean dose of lisinopril was 9.3
1.6 mg/day and frusemide was necessary for adequate control of
hypertension in only two patients. In the CA group, the mean
dose of nifedipine was 42 3 mg/day (40mg in 8 subjects, 60mg
in 2 and 20 mg in 1); atenolol had to be associated with
nifedipine in seven patients (in 3 for alleviation of flushing and
in 4 for achievement of adequate control of hypertension). Of
note, bilateral native kidney nephrectomy had been performed
in only one patient and diabetic nephropathy was the cause of
renal failure in one patient of the ACEI group. Two subjects in
each group received kidney from a living-related donor. The age
of donors as well as the number of acute rejections observed
before inclusion were similar in both groups.
Basal parameters
As summarized in Table 1, both groups were similar with
respect to pretreatment values of time elapsed after transplan-
tation, arterial pressure, serum creatinine, glomerular filtration
rate (range 43 to 95 in the ACEI group and 39 to 117 mi/mm!! .73
m2 in the CA group) and urinary excretion of albumin (82 33
in the ACEI group and 111 44 jig/mm in the CA group).
Filtration fraction was higher but not statistically different in the
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Follow-up period ACEI 12 1 30 2
months CA 10 1 30 2
Cyclosporine dose ACEI 7.2 0.7 4.4 0.3 3.5 o.2a
mg/kg/day CA 6.5 0.7 4.1 Ø4 3.4 0.4a
ACEI vs. CA NS NS NS
Cyclosporine trough level ACE! 141 14 103 8 116 18
ng/ml CA 152 13 102 9 97 13a
ACEL vs. CA NS NS NS
a P < 0.05 when compared to pretreatment value.
CA group. Cyclosporine dose and cyclosporine trough blood
levels were similar in both groups before and during the
follow-up period (Table 2).
Effect of antihypertensive therapy on arterial pressure
At the end of studies, body weight increased significantly but
to a higher extent (P < 0.05) in the ACE! group (9.2 1.9%)
when compared to the CA group (3.9 1.6%).
As shown in Figure 1, arterial pressure was similarly con-
trolled in both treatment groups. The decrease in mean arterial
pressure (MAP) was —12 3 (intermediate study) and —18 3
mm Hg (final study) in the ACE! group and —15 3 and —13
5 mm Hg, respectively, in the CA group. Heart rate was not
influenced by ACEI treatment whereas it decreased from 64
4 to 58 3 bpm (P < 0.02) in the CA group, probably due to the
addition of atenolol to nifedipine in 7 of 11 patients.
Effect of treatment on renal function
The effect of treatment on serum and urinary electrolytes is
depicted in Table 3. Overall, no change in serum sodium and
potassium was observed in the ACE! group, whereas a signif-
icant fall of serum potassium was observed in the CA group.
Interestingly, no change in urinary excretion of sodium and
urea, a rough estimate of dietary sodium and protein intakes,
was detected in both groups.
As shown in Figure 2, hematocrit, which was similar in both
groups before treatment (0.37 0.02 in the ACE! group and
0.37 0.02 in the CA group), remained unchanged in the ACEI
group (final value 0.38 0.013) and consistently increased to
0.43 0.02 (+15 3%) at the intermediate study and 0.44
0.024 (+20.2 4.3%) at the final study in the CA group. No
modification in serum protein concentration was noted in either
group. No correlation between changes in hematocrit and
changes in plasma protein concentration associated with anti-
hypertensive therapy were observed.
The effect of antihypertensive therapy on renal function is
depicted in Figure 1. No significant change in GFR expressed as
absolute value or corrected for body surface area occurred in
either group (from 59 5 to 56 3 mI/mm and from 62 6 to
68 7 mI/mm in ACE! and CA groups, respectively). There
was no difference between mean GFR values observed at the
end of studies (ANOVA). Creatinine clearance was simulta-
neously measured and the ratio of creatinine clearance to GFR
was calculated. This ratio, which was 1.4 0.08 and 1.46
0.08 in ACE! and CA groups, respectively, before treatment,
was not modified during follow-up studies. Effective renal
plasma flow was not significantly affected by treatment in either
group; however, renal vascular resistance decreased by 17.5
7.5% at the end of studies in the ACE! group and by 17.5 7%
in the CA group. Filtration fraction was significantly lower
when compared to the pretreatment values only at the end of
the follow-up in the ACEI group. Urinary albumin excretion
was not affected by treatment in either group. No correlation
was observed between pretreatment urinary albumin excretion
and baseline value of arterial pressure, GFR and filtration
fraction.
Hormonal changes
As depicted in Table 3, PRA consistently increased during
ACE! treatment whereas it rose to a lesser extent during
therapy in the CA group. No change in plasma aldosterone
concentration was observed in either group.
Discussion
In this prospective randomized study conducted in renal
transplant recipients maintained on cyclosporine, it was dem-
onstrated that the angiotensin-converting enzyme inhibitor,
lisinopril, given alone or in association with frusemide (2 of 14
patients) had a similar antihypertensive effect when compared
to the dihydropyridine derivative, nifedipine, alone or com-
bined with the beta blocker, atenolol (7 of 11 pts). Renal
function, assessed by the clearance of TCDTPA, a reliable
marker of GFR [191, remained stable throughout the mean
follow-up period of 30 months in the ACE! group, whereas a
trend for increase (not statistically significant) was observed in
the CA group. Both antihypertensive regimens resulted in a
significant decrease in renal vascular resistance. The finding of
a fall in the filtration fraction only in the ACEI group and only
at completion of follow-up suggests that the decrease in renal
resistance was preferentially located at the efferent glomerular
level. In contrast, no modification of the filtration fraction was
observed during treatment by the calcium antagonist, thus
indicating that renal vasodilatation might have taken place both
at the afferent and efferent glomerular arteriolar level. These
results suggest that ACE!, in contrast to calcium antagonists,
may result in a decrease in the intraglomerular capillary pres-
sure.
Due to the frequent observation of lower levels of PRA in
cyclosporine-treated transplant recipients when compared to
patients receiving conventional immunosuppressive therapy
[10, Il] and the marked reduction in arterial pressure following
acute administration of calcium antagonists in these patients, it



















Fig. 1. Effect of chronic treatment by
angiotensin-converting enzyme inhibitor (0,
ACE!) or calcium antagonist (•, CA) on
arterial pressure and renal function in
cyclosporine-treated renal transplant
recipients (intermediate study at about 1 year
and final study at 2.5 years of follow-up,
10 respectively). < 0.05 when compared to
pretreatment values.
was claimed that calcium antagonists may be more effective
antihypertensive agents than ACEI [1, 20]. In a recent personal
study, the acute effect of captopril on renal function was
assessed in patients maintained on cyclosporine or conven-
tional treatment. It was observed that acute ACEI did not affect
arterial pressure, creatinine clearance and renal hemodynamics
in the cyclosporine group, whereas a fall in arterial pressure,
consistent renal vasodilation and a decrease in the filtration
fraction occurred in patients maintained on conventional immu-
nosuppressive therapy [6, 11]. The finding in the present study,
that ACEI alone had a consistent antihypertensive effect, was
not really surprising since the chronic effect of ACEI on arterial
pressure has been shown to be poorly related to the pretreat-
ment level of plasma renin activity and is usually more marked
than their acute effect in both human and animal models of
hypertension [211. In marmosets, it was observed that cyclo-
sporine-induced hypertension was not sensitive to acute admin-
istration of the ACEI cilazapril but regressed to normal level
during chronic treatment [221. The exact mechanisms of the
chronic antihypertensive effect of ACEI in cyclosporine-treated
renal transplant recipients remain unclear. Treatment may have
modified sodium balance, reduced the sympathetic nervous
system activity which is known to be enhanced by cyclosporine
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Table 3. Changes in biochemical and hormonal parameters during the course of the studies
ACE inhibitor group Calcium antagonist group
Basal End of studies Basal End of studies
Serum creatinine 140 6 144 7 137 9 129 8
i.unol/liter
Serum sodium 138 0.9 138 0.6 139 0.7 139 0.7
mmo!/liter
Serum potassium 3.9 0.1 3.9 0.1 4.0 0.1 3.7 0.la
mmol/liter
Urinary sodium 159 18 146 13 160 23 182 26
mmol/24 hr
Urinary potassium 54 6 73 11 77 9 74 10
mmol/24 hr
Urinary urea 435 29 471 39 371 40 407 36
mmol/24 hr
Plasma renin activity 1.95 0.64 10.7 2.06k 1.41 0.22 3.46 0.76a
nglml/hr
Plasma aldosterone 10.4 1.3 9.0 1.1 11.1 1.7 10.7 0.9
ng/dl











Fig. 2. Changes in hematocrit associated with treatment by angioten-
sin-converting enzyme inhibitor (ACE!) or calcium antagonist (CA).
Intermediate study at about 1 year and final study at 2.5 years of
follow-up respectively. *f < 0.05 when compared to the pretreatment
values.
angiotensin II (mainly the vascular renin-angiotensin system)
[23]. In addition, non-renin mediated actions of ACE! should be
considered, although no unequivocal evidence exists for such a
possibility in the present model.
The antihypertensive effect of nifedipine was similar to that
of lisinopril within a follow-up period of approximately 30
months. It should be noted that the beta blocker atenolol was
necessary in order to alleviate undesirable side effects or to
potentiate the antihypertensive effect of nifedipine. At the
present time, no clear evidence was provided in favor of a
preferential use of calcium antagonists in cyclosporine-treated
subjects, except for the observation of a marked decrease in
arterial pressure following acute administration of CA and the
existence of low PRA levels and extracellular volume expan-
sion [10], which are conditions known to potentiate the antihy-
pertensive efficacy of calcium antagonists [24, 25]. However, it
should be noted that the use of calcium antagonists may confer
other advantages in cyclosporine-treated transplant recipients
such as the prevention of early acute renal failure [26] and acute
nephrotoxicity and the reduction of dosage allowing a substan-
tial cost containment [27].
The current investigation clearly showed that a satisfactory
control of hypertension was associated with the maintenance of
a constant GFR during a follow-up period of 30 months with
two different antihypertensive regimens. ACEI treatment was
initiated approximately five months after transplantation, with
CsA levels being kept below 150 nglml. If ACE! treatment is
given to patients with higher levels of CsA, a drop in GFR may
occur due to efferent arteriolar vasodilatation (ACEI) combined
with afferent arteriolar vasoconstriction (C5A). Although most
studies have shown that renal function progressively declines in
cyclosporine-treated patients, probably due to cyclosporine
nephrotoxicity [28, 29], it was recently reported that GFR may
remain stable within long follow-up periods (more than 2 years);
however, no data on arterial pressure and antihypertensive
treatment were provided [30]. The long-term stability of GFR
observed in the present study was associated with unchanged
renal plasma flow and consistent renal vasodilation in both
groups. Renal plasma flow was assessed as the clearance of
orthoiodohippurate without determination of the renal extrac-
tion ratio of this indicator. It was shown that ACEIs do not alter
the renal extraction of paraaminohippurate [31], whereas ni-
trendipine tended to induce a decrease in this parameter in dogs
[32]. If the latter observation could be applied to human studies,
*
*
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it would result in a higher value of true renal plasma flow in
patients on nifedipine therapy.
Although it could be inferred that the control of hypertension
per se may, in the present setting result in renal protection, as
it does in other renal diseases [1], the reduction in cyclosporine
dosage as well as blood trough levels may have significantly
participated to the observed protective effect. Of note, cyclo-
sporine levels were similar in the presence of identical mainte-
nance doses of cyclosporine in both ACEI and CA groups. This
confirms that nifedipine, in contrast to nicardipine [331, dilt-
iazem [34] and verapamil [35], does not result in an increase of
cyclosporine concentrations. It should also be pointed out that
our data do not allow conclusions to be drawn on the eventual
influence of ACE! or CA on the nephrotoxicity of cyclosporine.
Animal studies have demonstrated a rather poor effect of ACEI
on renal functional changes induced by short-term administra-
tion of cyclosporine [13]. In contrast, calcium antagonists
invariably blunted the renal functional consequences of cyclo-
sporine [15—17]. In renal transplant recipients, McNally, Wallis
and Feehally [361 observed that a four week period of treatment
by nifedipine resulted in a slight increase in GFR and no change
in renal vascular resistance and arterial pressure in normoten-
sive cyclosporine-treated patients. In addition, retrospective
studies using serum creatinine (as a marker of renal function)
have concluded that there is a renal protective effect of calcium-
channel blockers when compared to other antihypertensive
agents in cyclosporine-treated renal transplant patients [37].
The lack of precise measurement of GFR tends to lessen the
strength of their conclusions.
A marked increase in plasma renin activity was observed
during chronic ACEI treatment whereas poor stimulation of
renin secretion occurred after acute ACE! Ill]. This could be
related to the long-term lowering of systemic pressure or
progressive inhibition of the feedback mechanism between
circulating angiotensin II and renin release. It is also possible
that chronic ACEI may reverse the abnormality of the conver-
sion of prorenin into active renin [9] through some healing of
intrarenal vascular lesions (mainly the narrowing of the afferent
arterioles) associated with cyclosporine.
Following successful renal transplantation, correction of ane-
mia associated with terminal renal failure occurs within one to
three months [38]. In some patients, erythrocytosis may de-
velop whatever the immunosuppressive regimen [39, 40]. VIa-
hakos et a! [41] recently reported on a substantial decrease of
hematocrit from 0.42 to 0.33 within a treatment period of 12
weeks by enalapril. In another study [42], it was observed that
enalapril treatment corrected erythrocytosis in renal transplant
recipients maintained on cyclosporine. Similar observations
were made with the use of the sulfhydryl-containing ACE!,
captopril [43]. In the present investigations, hematocrit was
stable during the 30 month period of lisinopril treatment,
whereas a 20% increase in hematocrit occurred during treat-
ment with nifedipine. Interestingly, no change in total serum
protein level (and thus probably in plasma volume) was ob-
served. These observations suggest that lisinopril has prevented
an eventual increase in hematocrit, probably through an inhibi-
tion of the well-known erythropoietin-stimulating effect of the
renin-angiotensin system [44].
In conclusion, the current studies provide evidence that
angiotensin-converting enzyme inhibitors and calcium antago-
nists are useful medications for the control of hypertension in
renal transplant recipients who are maintained on cyclosporine
therapy. With regards to the long-term evolution of renal
function, no evidence was obtained in favor of the use of a
particular antihypertensive strategy. In contrast, the prevention
of post-transplant erythrocytosis seems to be specific with the
use of converting-enzyme inhibitors.
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